Rituximab biosimilar-Research Grade (MALS verified), Unconjugated, Human

Catalog Number: ABS-CD0-M36-500UG
Article Name: Rituximab biosimilar-Research Grade (MALS verified), Unconjugated, Human
Biozol Catalog Number: ABS-CD0-M36-500UG
Supplier Catalog Number: CD0-M36-500ug
Alternative Catalog Number: ABS-CD0-M36-500UG
Manufacturer: AcroBiosystems
Host: Human
Category: Antikörper
Species Reactivity: Mouse
Conjugation: Unconjugated
Blymphocyte antigen CD20 is also known as Blymphocyte surface antigen B1, Leukocyte surface antigen Leu16, Membranespanning 4domains subfamily A member 1 and MS4A1, is an activatedglycosylated phosphoprotein expressed on the surface of all Bcells beginning at the proB phase (CD45R+, CD117+) and progressively increasing in concentration until maturity. CD20 is expressed on all stages of B cell development except the first and last, it is present from late proB cells through memory cells, but not on either early proB cells or plasma blasts and plasma cells. It is found on Bcell lymphomas, hairy cell leukemia, Bcell chronic lymphocytic leukemia, and melanoma cancer stem cells. The protein has no known natural ligand and its function is to enable optimal Bcell immune response, specifically against Tindependent antigens. It is suspected that it acts as a calcium channel in the cell membrane. CD20 / MS4A1 is the target of the monoclonal antibodies (mAb) rituximab, Ibritumomab tiuxetan, and tositumomab, which are all active agents in the treatment of all B cell lymphomas and leukemias. Defects in CD20 / MS4A1 are the cause of immunodeficiency common variable type 5 (CVID5), also called antibody deficiency due to CD20 defect. CVID5 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen. - Antikörper
Tag: Human IgG1 | Human Kappa
Buffer: PBS, pH7.4
Purity: 0.95
Form: Powder
Target: CD20
Immobilized Rituximab biosimilar (Cat. No. CD0-M36) at 2 µg/mL (100 µL/well) can bind Human CD20 Full Length Protein, His Tag (Cat. No. CD0-H52H3) with a linear range of 0.2-10 ng/mL (QC tested).
Rituximab biosimilar on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 0.95.